164 related articles for article (PubMed ID: 33014332)
1. Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
Underwood B; Zhao Q; Walker AR; Mims AS; Vasu S; Long M; Z Haque T; Blaser BW; Grieselhuber NR; Wall SA; Behbehani GK; Blachly JS; Larkin K; Byrd JC; Garzon R; Wang TF; Bhatnagar B
Int J Hematol Oncol; 2020 Sep; 9(3):IJH28. PubMed ID: 33014332
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism incidence associated with pegylated asparaginase (ASP) compared to the native L-ASP: A retrospective analysis with an ASP-based protocol in adult patients with acute lymphoblastic leukaemia.
Chen R; Atenafu EG; Seki J; Liu X; Chan S; Gupta V; Maze D; Shuh AC; Minden MD; Yee K; Schimmer AD; Sibai H
Br J Haematol; 2023 May; 201(4):645-652. PubMed ID: 36794878
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
Lee JH; Lee J; Yhim HY; Oh D; Bang SM
J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens.
Kashanian SM; Holtzman NG; Patzke CL; Cornu J; Duffy A; Koka M; Niyongere S; Duong VH; Baer MR; Apata J; Kamangar F; Emadi A
Cancer Chemother Pharmacol; 2021 Jun; 87(6):817-826. PubMed ID: 33677674
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Chen J; Ngo D; Aldoss I; Shayani S; Tsai NC; Pullarkat V
Leuk Lymphoma; 2019 May; 60(5):1187-1192. PubMed ID: 30322332
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy.
Sibai H; Chen R; Liu X; Falcone U; Schimmer A; Schuh A; Law A; McNamara C; Maze D; Yee K; Minden M; Chan SM; Gupta V; Murphy T; Sakurai N; Atenafu EG; Brandwein JM; Seki JT
Br J Haematol; 2020 Dec; 191(5):748-754. PubMed ID: 32395867
[TBL] [Abstract][Full Text] [Related]
7. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
8. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation.
Freyer CW; Carulli A; Ganetsky A; Hughes ME; Krause TM; Timlin C; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy SR; Perl AE; Pratz K; Porter DL; Luger SM
Leuk Lymphoma; 2020 Sep; 61(9):2200-2207. PubMed ID: 32482107
[TBL] [Abstract][Full Text] [Related]
10. Solving coagulation conundrums: comparing prophylaxis strategies in adult patients receiving PEG-asparaginase.
Chen Y; Buhlinger K; Perissinotti AJ; Schepers AJ; Benitez L; Auten J; Chen SL; Bixby DL; Burke PW; Pettit KM; Marini BL
Leuk Lymphoma; 2022 Nov; 63(11):2663-2670. PubMed ID: 35699966
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation.
Lauw MN; Van der Holt B; Middeldorp S; Meijers JC; Cornelissen JJ; Biemond BJ
Thromb Haemost; 2013 Apr; 109(4):633-42. PubMed ID: 23364346
[TBL] [Abstract][Full Text] [Related]
12. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
[TBL] [Abstract][Full Text] [Related]
13. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
Goyal G; Bhatt VR
Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
[TBL] [Abstract][Full Text] [Related]
14. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
[TBL] [Abstract][Full Text] [Related]
15. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.
Grace RF; DeAngelo DJ; Stevenson KE; Neuberg D; Sallan SE; Mourad YRA; Bergeron J; Seftel MD; Kokulis C; Connors JM
J Thromb Thrombolysis; 2018 Feb; 45(2):306-314. PubMed ID: 29260426
[TBL] [Abstract][Full Text] [Related]
16. Risk of Thrombosis in Adult Philadelphia-Positive ALL Treated with an Asparaginase-Free ALL Regimen.
Chen R; Liu X; Law AD; Kanfar S; Maze D; Chan SM; Gupta V; Yee KW; Minden MD; Schimmer AD; Schuh AC; McNamara CJ; Murphy T; Xu A; Falcone U; Seki J; Sibai H
Curr Oncol; 2020 Dec; 28(1):128-137. PubMed ID: 33704181
[TBL] [Abstract][Full Text] [Related]
17. Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia.
Zuurbier SM; Lauw MN; Coutinho JM; Majoie CB; van der Holt B; Cornelissen JJ; Middeldorp S; Biemond BJ; Stam J
J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1679-84. PubMed ID: 25934140
[TBL] [Abstract][Full Text] [Related]
18. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia.
Sibai H; Seki JT; Wang TQ; Sakurai N; Atenafu EG; Yee KW; Schuh AC; Gupta V; Minden MD; Schimmer AD; Brandwein JM
Curr Oncol; 2016 Aug; 23(4):e355-61. PubMed ID: 27536184
[TBL] [Abstract][Full Text] [Related]
20. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia.
Prasca S; Carmona R; Ji L; Ko RH; Bhojwani D; Rawlins YA; Mittelman SD; Young G; Orgel E
Thromb Res; 2018 May; 165():44-50. PubMed ID: 29567586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
